Market Overview

Inovio Says Study Shows Robust Vaccine Antibody Response; Positive Results on Leukemia DNA Vaccine

Share:
Related INO
51 Biggest Movers From Yesterday
Benzinga's Top Upgrades, Downgrades For October 18, 2017

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.

Posted-In: News FDA Legal

 

Related Articles (INO)

View Comments and Join the Discussion!

Partner Center